Effect of ranizumab combined with whole retinal photocoagulation on proliferative diabetes retinopathy
雷珠单抗联合全视网膜光凝治疗增生性糖尿病视网膜病变的效果

摘要

目的 对于增生性糖尿病视网膜病变（PDR）采用雷珠单抗+全视网膜光凝治疗，分析其治疗效果。方法 此次研究所纳入的PDR患者（n=70），均为我院2018.5~2020.5月收治，根据治疗方法不同进行分组。分为35例对照组（全视网膜光凝治疗）和35例实验组（雷珠单抗+全视网膜光凝治疗）。观察两组治疗前后矫正视力、黄斑中心凹视网膜神经上皮厚度和不良反应发生率变化。结果 同治疗前相比，患者治疗1周、4周、3个月和半年后矫正视力在不断改善，但实验组矫正视力高于对照组（P<0.05）；患者经治疗后，同治疗前相比，黄斑中心厚度在不断下降，但实验组显著低于对照组（P<0.05）；两组不良反应发生率相比，差异不具有统计学意义（p＞0.05）。结论 将雷珠单抗+全视网膜光凝治疗方法应用于PDR治疗过程中，疗效安全，能够有效改善患者的视力，治疗效果较为理想，值得推广。

Abstract

Objective: to treat proliferative diabetes retinopathy (PDR) with ranizumab and whole retinal photocoagulation, and analyze the therapeutic effect.
Methods: the PDR patients (n = 70) included in this study were all admitted to our hospital from May 2018 to may 2020, and were grouped according to different treatment methods. They were divided into 35 control groups (whole retinal photocoagulation) and 35 experimental groups (ranizumab + whole retinal photocoagulation). The changes of corrected visual acuity, retinal neuroepithelial thickness in macular fovea and incidence of adverse reactions were observed before and after treatment.
Results: compared with before treatment, the corrected visual acuity of the patients was improved continuously after 1 week, 4 weeks, 3 months and half a year of treatment, but the corrected visual acuity of the experimental group was higher than that of the control group (P < 0.05); After treatment, compared with that before treatment, the central macular thickness of patients in the experimental group was continuously decreased, but it was significantly lower than that in the control group (P < 0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05).
Conclusion  : the application of ranizumab + whole retinal photocoagulation in the treatment of PDR is safe and can effectively improve the visual acuity of patients. The treatment effect is ideal and worthy of promotion.